<span id="midArticle_start"/>May 5 (Reuters) - Kancera AB :
<span id="midArticle_0"/>* Gives operational update for cancer projects
<span id="midArticle_1"/>* Calculations show that Kancera's drug candidate KAN0439834 is likely tohave characteristics that provide a desired effect against cancer in humans withan oral therapy 2-3 times per day
<span id="midArticle_2"/>Source text for Eikon:
<span id="midArticle_3"/>Further company coverage: (Gdynia Newsroom)
<span id="midArticle_4"/>
<span id="midArticle_0"/>* Gives operational update for cancer projects
<span id="midArticle_1"/>* Calculations show that Kancera's drug candidate KAN0439834 is likely tohave characteristics that provide a desired effect against cancer in humans withan oral therapy 2-3 times per day
<span id="midArticle_2"/>Source text for Eikon:
<span id="midArticle_3"/>Further company coverage: (Gdynia Newsroom)
<span id="midArticle_4"/>
via Smart Health Shop Forum http://ift.tt/1GXmadK
No comments:
Post a Comment